Missed a GLP-1 dose? What it actually costs you

First: what to actually do is on your leaflet

Every product has its own instruction for a missed dose, and it is specific – how many days late is still acceptable, whether to take it or skip it, and when the schedule can be moved. That instruction is printed on your leaflet and your prescriber or pharmacist can confirm it for the product you were dispensed.

Penwise is a tracker. It records what you did and shows you what it means for your level. It does not tell you whether to take a late dose, and this guide does not either. What follows is the arithmetic behind why the leaflets differ – which is worth understanding, because it is the thing nobody explains.

The half-life decides everything

Population figures from published pharmacokinetics. Individual clearance varies.

That last row is not a typo. Liraglutide loses in a day roughly what semaglutide loses in a month. It is a completely different pharmacological situation wearing the same category label, and it is why “just take it when you remember” is safe general advice for some of these drugs and meaningless for another.

Semaglutide: a forgiving drug

With a seven-day half-life against a seven-day interval, semaglutide has more slack than any other product here. A dose taken one or two days late leaves your level barely distinguishable from where it would have been. Even several days late, you are still inside the range your level occupies during a normal week.

A fully missed week is more visible: instead of arriving at 50% of your last dose you arrive at about 25%, and the following dose stacks on less. The recovery is undramatic, though – a couple of weeks of normal dosing and the level is back on its plateau. Most people report the missed week itself as harder than the weeks after it, which matches the curve. The detail is in how long semaglutide stays in your system.

Tirzepatide: less forgiving than it looks

A five-day half-life against a seven-day interval means tirzepatide is already running a deeper weekly trough than semaglutide before anything goes wrong. Lateness digs into a dip that was steeper to begin with.

One day late is a real if modest dip. Three days late and you are approaching the bottom of what a normal week would produce. A full week missed leaves roughly an eighth of the last dose, and the week that follows very often feels like starting over – because in level terms it partly is.

This is the mechanism behind the widely-reported experience of “the week after a missed shot was awful”. It is not imagination and it is not a rebound; it is a trough that went deeper and lasted twice as long. See how long tirzepatide stays in your system.

Liraglutide: a missed day is a real gap

At about thirteen hours, liraglutide is effectively gone within two to three days of stopping. A missed day is not a dip in a long tail – it is most of the way back to nothing.

That is why the daily products have their own missed-dose instruction and why re-titration comes up if the gap is long. If you have been off it for a while, restarting at the dose you left is not automatically the plan, and that is a conversation with your prescriber rather than a decision to make from a chart. Tracking Saxenda and Victoza covers what daily dosing changes.

Oral semaglutide: the drug forgives, the habit does not

Rybelsus and the other tablets share semaglutide half-life, so a single missed tablet has almost no effect on your level. The problem with dailies is not the pharmacology, it is the frequency: a weekly injection is missed a few times a year, and a daily tablet is missed whenever a morning goes differently.

A run of missed mornings does add up, and it also usually has a cause – the fasting window colliding with a schedule, travel, a change in routine. Those are patterns you can see in a calendar and cannot see in your head. See tracking oral semaglutide.

The dose-shifting drift nobody notices

The far more common problem is not a missed dose at all. It is drift: Monday becomes Tuesday becomes Wednesday, half a day at a time, until your injection day has moved and you have no idea when it happened.

Drift is invisible in a log that only records dates, because every individual entry looks fine. It shows up only as a trend, and Penwise reports it as one of its four insight types: whether you are taking doses on time and by how much you tend to run late. Not as a scolding – as a fact you can act on, because a schedule that has quietly slid three days is worth knowing about before it collides with a pen discard window.

Getting back on track

1. 01 Log the miss. A gap that is not recorded is a gap that will confuse every later question about what happened.
2. 02 Follow the leaflet for your product, or ask your pharmacist. That is the actual answer to “what do I do”.
3. 03 Expect the following week to feel different, especially on tirzepatide, and do not read that as the medication failing.
4. 04 Check the pen clock. A skipped week pushes a four-dose pen towards its discard date, and on a 30-day KwikPen that is often the collision point.
5. 05 Do not double up to compensate unless your prescriber tells you to. Nothing in a level chart justifies that decision.

What Penwise does with it

A dose can be skipped, postponed or rescheduled, individually, with the history of what you decided kept rather than overwritten. A late dose stays visible as late instead of quietly becoming the new normal. Reminders are scheduled months ahead – not one at a time – so they keep arriving even during the stretch where you have stopped opening the app, which is precisely when doses get missed.

And with Penwise+, the estimated level curve shows what the gap actually did, which for most people is the first time a missed dose becomes a size rather than a feeling.

Common questions

Sources

Every factual claim on this page traces to the product information a regulator publishes, or to a published trial. Links open on the site of whoever issued the document.

1. Mounjaro: EPAR product information European Medicines Agency
2. Ozempic: EPAR product information European Medicines Agency
3. Wegovy: EPAR product information European Medicines Agency

Penwise is a tracking and education tool, not a medical device. Nothing on this page is medical advice, a diagnosis or a recommendation to start, stop or change a dose. Dosing decisions belong to you and your clinician. Ozempic, Wegovy, Rybelsus, Saxenda and Victoza are trademarks of Novo Nordisk; Mounjaro, Zepbound and Trulicity are trademarks of Eli Lilly. Penwise is not affiliated with, endorsed by or connected to either company.